Meeting
2019 ASCO Annual Meeting
A phase II trial of preoperative chemoradiotherapy and pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC).
Authors
Min Hee Hong
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea
Min Hee Hong , HyeRyun Kim , Seong Yong Park , Dae Joon Kim , Chang Geol Lee , Jaeho Cho , Jong Hoon Kim , Hyeong Ryul Kim , Yong-Hee Kim , Sook Ryun Park , Byoung Chul Cho
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT02844075
Citation
J Clin Oncol 37, 2019 (suppl; abstr 4027)
DOI
10.1200/JCO.2019.37.15_suppl.4027
Abstract #
4027
Poster Bd #
132
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.
First Author: Richard Francis Dunne
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Adjuvant chemoradiotherapy (CRT) plus pembrolizumab for locally advanced esophageal squamous cell carcinoma (ESCC) with high risk of recurrence after neoadjuvant CRT plus surgery: A single-arm phase II study.
First Author: Jhe-Cyuan Guo
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Neoadjuvant anlotinib combined with penpulimab for resectable locally advanced esophageal squamous cell carcinoma (ESCC): A prospective, single-arm, phase II trial.
First Author: yueyun chen
Poster
2023 ASCO Annual Meeting
Predictive value of tumor-infiltrating lymphocyte (TIL) dynamics in the tumor microenvironment (TME) during preoperative chemoradiotherapy (CRT) on pathologic complete response (pCR) in microsatellite-stable (MSS) locally advanced rectal cancer (LARC).
First Author: Mitsuho Imai